Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts– March 29, 2023 — ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology business concentrated on the generation and advancement of antibody therapies targeting hazardous misfolded proteins in neurodegenerative illness such as Alzheimer’s illness (ADVERTISEMENT), amyotrophic lateral sclerosis (ALS) and numerous system atrophy (MSA), today provided brand-new in vitro preclinical information supporting the distinction of PMN310 from other amyloid-beta (Aβ)-directed antibodies at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders (AD/PD 2023). Antibody treatments that target Aβ in advertisement continue to produce interest with current approvals and brand-new prospective treatments in advancement. A big body of proof recommends that soluble hazardous Aβ oligomers, instead of Aβ monomers or plaque, are the primary chauffeur of synaptic dysfunction, neuronal loss and cognitive decrease in advertisement clients. It has actually been a difficulty to particularly target hazardous oligomers considering that they are the least plentiful type of Aβ in the brain. In preclinical research studies, ProMIS Neurosciences’ lead prospect, PMN310, has actually shown its capability to selectively target pathogenic Aβ oligomers without ineffective binding to non-toxic monomers or plaque. “We think these motivating information assist separate our lead restorative prospect, PMN310, from other Aβ-directed antibodies. As displayed in our AD/PD poster, PMN310 selectively targeted poisonous oligomers and prevented interaction with plaque and vascular deposits,” stated Johanne Kaplan, Ph.D., Chief Development Officer of ProMIS Neurosciences. “We think that these information support scientific advancement of PMN310, and we are thrilled to send an IND application in the coming weeks as we advance our strategies to bring a next-generation treatment to clients experiencing Alzheimer’s illness.” Dr. Kaplan will be spoken with by VJNeurology throughout the AD/PD conference. Hyperlinks will be published to the Events page of the ProMIS site when offered. In a poster discussion entitled, “Differentiation of PMN310 from other amyloid-beta-directed antibodies: Ability to selectively target harmful brain oligomers regardless of contending monomers and plaque,” surface area plasmon resonance was utilized to evaluate the binding of several Aβ-directed antibodies (PMN310, donanemab, aducanumab, lecanemab, crenezumab, solanezumab, gantenerumab) to a harmful oligomer-enriched low molecular weight portion of soluble brain extract from advertisement clients, with and without pre-exposure to completing monomers. The antibodies that finest prevented monomer competitors and maintained quantifiable binding to advertisement brain harmful oligomers (aducanumab, lecanemab, donanemab) have actually likewise created favorable lead to medical trials. Antibodies that might not get rid of monomer competitors have actually produced unfavorable scientific trial outcomes. In this side-by-side contrast in a nonclinical assay, PMN310 was the least affected by monomer competitors, leading to a total higher poisonous oligomer binding level versus all comparators. Even more, in contrast to the other Aβ-directed antibodies, PMN310 did not bind to plaque or vascular deposits in advertisement brain, recommending that it might bring a lowered danger of dose-limiting ARIA (amyloid-related imaging irregularities) adverse effects related to plaque-binding antibodies. The discussion is offered on the Events page of the business’s site at www.promisneurosciences.com About ProMIS Neurosciences Inc. ProMIS Neurosciences Inc. is an advancement phase biotechnology business concentrated on creating and establishing antibody rehabs selectively targeting harmful misfolded proteins in neurodegenerative illness such as Alzheimer’s illness (ADVERTISEMENT), amyotrophic lateral sclerosis (ALS) and several system atrophy (MSA). The Company’s exclusive target discovery engine is based upon making use of 2 complementary methods. The Company uses its thermodynamic, computational discovery platform – ProMIS ™ and Collective Coordinates – to forecast unique targets referred to as Disease Specific Epitopes on the molecular surface area of misfolded proteins. Utilizing this distinct method, the Company is establishing unique antibody therapies for advertisement, ALS and MSA. ProMIS has workplaces in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is noted on Nasdaq and the Toronto Stock Exchange under the sign PMN. Forward-Looking Statements Neither the TSX nor
Learn more